论文部分内容阅读
目的探讨23价肺炎球菌多糖疫苗(PenV23)和流感裂解疫苗(Infv-B)联合接种在慢性阻塞性肺病(COPD)患者防治中的临床意义。方法将50例COPD患者按知情同意自愿的原则随机分成疫苗组和对照组。疫苗组患者于观察开始前注射PenV23 1次,并于流感高发季节前接种Infv-B。两组患者均观察2年,每月随访1次。对咳嗽、咳痰、气喘等症状进行临床评价;登记两组患者在2年内急性发作次数、天数、住院次数、平均住院天数和再发肺部感染的相距时间、住院费用。结果疫苗组急性发作次数、天数、住院次数、平均住院天数明显低于对照组,而再发肺部感染的相距时间延长,住院费用低。结论 PenV23和Infv-B联合接种能有效减少高原地区慢性阻塞性肺病感染复发率,是临床上防治慢性阻塞性肺病患者的一个有效方法,值得推广。
Objective To investigate the clinical significance of the combination of 23-valent pneumococcal polysaccharide vaccine (PenV23) and influenza lysed vaccine (Infv-B) in the prevention and treatment of chronic obstructive pulmonary disease (COPD). Methods Fifty patients with COPD were randomly divided into vaccine group and control group according to the principle of voluntary consent. Patients in the vaccine group were injected with PenV23 1 time prior to the start of the observation and Infv-B was vaccinated prior to the flu season. Two groups of patients were observed for 2 years, a monthly follow-up. Cough, sputum, asthma and other symptoms of clinical evaluation; registered two groups of patients within 2 years of acute exacerbation, the number of days, the number of hospitalizations, the average length of stay and recurrent pulmonary infection in the time and hospitalization costs. Results The numbers of acute attacks, days, hospitalizations and average days of hospitalization in the vaccine group were significantly lower than those in the control group, while the interval between recurrent pulmonary infections was longer and the hospitalization costs were lower. Conclusion The combination of PenV23 and Infv-B can effectively reduce the recurrence rate of chronic obstructive pulmonary disease in the plateau area, which is an effective method to prevent and treat chronic obstructive pulmonary disease in clinic. It is worth to be popularized.